Vanguard Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-405,474
| Closed | -$251K | – | 4197 |
|
|
2018
Q4 | $251K | Sell |
405,474
-809,667
| -67% | -$841K | ﹤0.01% | 3860 |
|
|
2018
Q3 | $1.58M | Buy |
1,215,141
+1,800
| +0.1% | +$2.79K | ﹤0.01% | 3603 |
|
|
2018
Q2 | $1.64M | Sell |
1,213,341
-86,622
| -7% | -$133K | ﹤0.01% | 3559 |
|
|
2018
Q1 | $1.89M | Buy |
1,299,963
+440,703
| +51% | +$920K | ﹤0.01% | 3477 |
|
|
2017
Q4 | $1.93M | Buy |
859,260
+21,999
| +3% | +$55.7K | ﹤0.01% | 3427 |
|
|
2017
Q3 | $2.85M | Buy |
837,261
+98,726
| +13% | +$332K | ﹤0.01% | 3301 |
|
|
2017
Q2 | $2.62M | Sell |
738,535
-83,709
| -10% | -$276K | ﹤0.01% | 3300 |
|
|
2017
Q1 | $2.8M | Buy |
822,244
+106,488
| +15% | +$414K | ﹤0.01% | 3270 |
|
|
2016
Q4 | $3.29M | Buy |
715,756
+63,496
| +10% | +$262K | ﹤0.01% | 3194 |
|
|
2016
Q3 | $2.77M | Buy |
652,260
+159,999
| +33% | +$518K | ﹤0.01% | 3272 |
|
|
2016
Q2 | $1.18M | Buy |
492,261
+43,008
| +10% | +$155K | ﹤0.01% | 3561 |
|
|
2016
Q1 | $2.11M | Sell |
449,253
-1,500
| -0.3% | -$5.8K | ﹤0.01% | 3352 |
|
|
2015
Q4 | $1.77M | Sell |
450,753
-43,513
| -9% | -$200K | ﹤0.01% | 3440 |
|
|
2015
Q3 | $1.91M | Sell |
494,266
-194,666
| -28% | -$894K | ﹤0.01% | 3402 |
|
|
2015
Q2 | $3.17M | Buy |
688,932
+180,466
| +35% | +$1.73M | ﹤0.01% | 3215 |
|
|
2015
Q1 | $3.43M | Buy |
+508,466
| New | +$2.52M | ﹤0.01% | 3182 |
|
Vanguard Group's AST Position: Q1 2019 in Review
Vanguard Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 405,474 shares — an estimated $251K sold.
Vanguard Group first reported a position in AST in Q1 2015 and held it in 16 quarters. The position peaked at $3.43M in Q1 2015. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Vanguard Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Vanguard Group sold 405,474 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $251K.
- Vanguard Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2015 and held it in 16 quarters.
- Vanguard Group's Asterias Biotherapeutics Inc. Series A position peaked at $3.43M in Q1 2015.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Vanguard Group's 13F filing for Q1 2019, filed 15 May 2019.